April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab significantly improves psoriasis symptoms within 12 weeks.
February 2010 in “Journal of The American Academy of Dermatology” Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
25 citations
,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.